Headquartered in Foster City, CA Fiscal year ends December NASDAQ: MIRM mirumpharma.com
Mirum Pharmaceuticals (NASDAQ: MIRM) is a rare disease biopharmaceutical company focused on rare liver and rare genetic diseases. Its commercial portfolio includes LIVMARLI (maralixibat), an ileal bile acid transporter (IBAT) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC); CHOLBAM (cholic acid), the first FDA-approved treatment for bile acid synthesis disorders; and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). The company's clinical-stage pipeline includes volixibat (IBAT inhibitor in late-stage development for primary sclerosing cholangitis and primary biliary cholangitis), brelovitug (a fully human monoclonal antibody in Phase 3 development for chronic hepatitis delta virus), zilurgisertib (an ALK2 inhibitor under FDA Priority Review for fibrodysplasia ossificans progressiva with a PDUFA date of September 26, 2026), and MRM-3379 (a PDE4D inhibitor in Phase 2 for Fragile X syndrome). Mirum markets its products globally and generates revenue primarily through net product sales of LIVMARLI and its bile acid medicines. Updated
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
Mirum Pharmaceuticals (NASDAQ: MIRM) is a rare disease biopharmaceutical company focused on rare liver and rare genetic diseases.
The Wall Street consensus 12-month price target for MIRM is $145.79.
